|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of the 17 beta-hydroxysteroid dehydrogenase (17-HSD) gene in a series of human breast cancer cell lines was studied by Northern blot hybridization with a cDNA probe and by a time-resolved immunofluorometric assay using polyclonal antibodies against the enzyme protein.
|
1728403 |
1992 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of the 17 beta-hydroxysteroid dehydrogenase (17-HSD) gene in a series of human breast cancer cell lines was studied by Northern blot hybridization with a cDNA probe and by a time-resolved immunofluorometric assay using polyclonal antibodies against the enzyme protein.
|
1728403 |
1992 |
|
Choriocarcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Regulation of aromatase cytochrome P-450 and 17 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels in choriocarcinoma cells.
|
1309352 |
1992 |
|
Choriocarcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Regulation of 3 beta-hydroxysteroid dehydrogenase and 17 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels by cyclic adenosine 3',5'-monophosphate and phorbol myristate acetate in human choriocarcinoma cells.
|
8387158 |
1993 |
|
Hereditary Breast and Ovarian Cancer Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The human estradiol 17 beta-hydroxysteroid dehydrogenase II (17 beta-HSD II) gene has been assigned by somatic cell hybridization to chromosome 17q11-q21, near the region of assignment of the gene BRCA1, which is involved in hereditary breast-ovarian cancer.
|
8389226 |
1993 |
|
Choriocarcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
17 beta-Hydroxysteroid dehydrogenase: enzymatic activity and mRNA species in choriocarcinoma cells.
|
8005555 |
1994 |
|
Sporadic Breast Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Human familial and sporadic breast cancer: analysis of the coding regions of the 17 beta-hydroxysteroid dehydrogenase 2 gene (EDH17B2) using a single-strand conformation polymorphism assay.
|
8125484 |
1994 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Estrone sulfate-sulfatase and 17 beta-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence.
|
7626488 |
1995 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Estrone sulfate-sulfatase and 17 beta-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence.
|
7626488 |
1995 |
|
Benign Prostatic Hyperplasia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Significantly higher expressions of 17HSD type 2 and 5alpha-reductase type 2 were detected in benign prostatic hyperplasia compared with the carcinoma specimens.
|
8608963 |
1996 |
|
Choriocarcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Regulation of cytochrome P450 cholesterol side-chain cleavage, 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase type 1 and estradiol-17 beta-hydroxysteroid dehydrogenase mRNA levels by calcium in human choriocarcinoma JEG-3 cells.
|
9359473 |
1997 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
17Beta-hydroxysteroid dehydrogenase (17-HSD) type I is present and active in most breast cancer cell lines where it modulates local estrogen availability.
|
9879985 |
1998 |
|
Endometriosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrated, by Northern blotting, 17betaHSD-2 messenger ribonucleic acid (RNA) in all RNA samples of secretory eutopic endometrium (n=12) but not in secretory samples of endometriotic lesions (n=10), including paired samples of endometrium and endometriosis obtained simultaneously from eight patients.
|
9851796 |
1998 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
17Beta-hydroxysteroid dehydrogenase (17-HSD) type I is present and active in most breast cancer cell lines where it modulates local estrogen availability.
|
9879985 |
1998 |
|
Malignant neoplasm of prostate
|
0.060 |
Biomarker
|
disease |
BEFREE |
The aim of this study on testosterone (T) metabolism in benign prostatic hyperplasia (BPH) and prostatic cancer was to compare the formation of metabolites in freshly isolated epithelial cells and in cells of long-term cultures (2 passages) and to identify the 5alpha-reductase (5alpha-R) and 17beta-hydroxysteroid dehydrogenase (17beta-HSD) isoforms responsible for metabolite formation.
|
9506528 |
1998 |
|
Male Pseudohermaphroditism
|
0.050 |
Biomarker
|
disease |
BEFREE |
Basal hormonal levels, and after human chorionic gonadotrophin stimulation, suggested a deficiency in 17beta-HSD as the biochemical defect underlying this MPH.
|
9758445 |
1998 |
|
Male Pseudohermaphroditism
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
We studied the molecular genetics of a large isolated inbred Turkish kindred with MPH due to either 5 alpha-reductase-2 (SRD5A2) or 17 beta-hydroxysteroid dehydrogenase-3 (17 beta HSD3) gene defects.
|
9467575 |
1998 |
|
Male Pseudohermaphroditism
|
0.050 |
Biomarker
|
disease |
BEFREE |
Testosterone is essential for the correct development of male internal and external genitalia; hence, deleterious mutations in the HSD17B3 gene give rise to a rare form of male pseudohermaphroditism termed 17betaHSD deficiency.
|
9709959 |
1998 |
|
Benign Prostatic Hyperplasia
|
0.030 |
Biomarker
|
disease |
BEFREE |
The aim of this study on testosterone (T) metabolism in benign prostatic hyperplasia (BPH) and prostatic cancer was to compare the formation of metabolites in freshly isolated epithelial cells and in cells of long-term cultures (2 passages) and to identify the 5alpha-reductase (5alpha-R) and 17beta-hydroxysteroid dehydrogenase (17beta-HSD) isoforms responsible for metabolite formation.
|
9506528 |
1998 |
|
pseudohermaphrodite (non-specific)
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The identification of 5 alpha-reductase-2 and 17 beta-hydroxysteroid dehydrogenase-3 gene defects in male pseudohermaphrodites from a Turkish kindred.
|
9467575 |
1998 |
|
Polycystic Ovary Syndrome
|
0.270 |
AlteredExpression
|
disease |
BEFREE |
Collectively, these observations establish that increased CYP11A and CYP17 mRNA expression, as well as increased CYP17, 3beta-hydroxysteroid dehydrogenase, and 17beta-hydroxysteroid dehydrogenase enzyme activity per theca cell, and consequently increased production of P4, 17OHP4, and T, are stable properties of PCOS theca cells.
|
10379893 |
1999 |
|
Endometriosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Additionally, endometriotic glandular cells are deficient in 17beta-hydroxysteroid dehydrogenase type 2, which converts E2 to estrone in the eutopic endometrium in response to P. Deficiency of this enzyme in endometriosis impairs the inactivation of E2 and may be a consequence of insensitivity to P.
|
10593363 |
1999 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
All except one tumour expressed at least one isoform of 17-HSD, either alone or in combination with aromatase and STS.
|
10574257 |
1999 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
17BetaHSD type 1 gene expression was detected in 34 of 42 adenomas in all tumor subtypes; 17betaHSD type 2 mRNA was detected in 18 of 42 adenomas, but not in prolactinomas; 17betaHSD type 3 mRNA was detected in 12 of 42 adenomas, but not in corticotropinomas; 17betaHSD type 4 was expressed in 20 of 42 adenomas by all adenoma subtypes.
|
10199776 |
1999 |
|
Male Pseudohermaphroditism
|
0.050 |
Biomarker
|
disease |
BEFREE |
In a nationwide study on male pseudohermaphroditism among all pediatric endocrinologists and clinical geneticists in The Netherlands, 18 17betaHSD3-deficient index cases were identified, 12 of whom initially had received the tentative diagnosis androgen insensitivity syndrome (AIS).
|
10599740 |
1999 |